The review essay by Donald Light about a Congressional Budget Office report on pharmaceutical research and development (R&D) (7) contains factual errors, leaves the reader uninformed about rebuttal responses to criticisms made in the review about studies of R&D costs, and draws erroneous conclusions about the nature of industry economics.
Commentary| April 01 2008
Misleading Congress About Drug Development: Reply
J Health Polit Policy Law (2008) 33 (2): 319–324.
Joseph A. DiMasi, Ronald W. Hansen, Henry G. Grabowski; Misleading Congress About Drug Development: Reply. J Health Polit Policy Law 1 April 2008; 33 (2): 319–324. doi: https://doi.org/10.1215/03616878-2007-063
Download citation file: